Compare JVA & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JVA | DARE |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 20.6M |
| IPO Year | 1997 | 2014 |
| Metric | JVA | DARE |
|---|---|---|
| Price | $3.17 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 25.8K | ★ 63.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $90,655,294.00 | $2,807,885.00 |
| Revenue This Year | N/A | $3,843.33 |
| Revenue Next Year | N/A | $8,700.33 |
| P/E Ratio | $12.52 | ★ N/A |
| Revenue Growth | ★ 17.54 | N/A |
| 52 Week Low | $2.76 | $1.42 |
| 52 Week High | $5.62 | $9.19 |
| Indicator | JVA | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 49.02 | 33.02 |
| Support Level | $2.93 | N/A |
| Resistance Level | $3.25 | $1.74 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 86.21 | 18.75 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.